Manfredi Rizzo1, Nicola Abate, Manisha Chandalia, Ali A Rizvi, Rosaria V Giglio, Dragana Nikolic, Antonella Marino Gammazza, Ignazio Barbagallo, Esma R Isenovic, Maciej Banach, Giuseppe Montalto, Giovanni Li Volti. 1. Biomedical Department of Internal Medicine and Medical Specialties (M.R., R.V.G., D.N., G.M.), University of Palermo, Palermo 90127, Italy; Euro-Mediterranean Institute of Science and Technology (M.R., A.M.G., I.B., G.L.V.), Palermo 90139, Italy; Division of Endocrinology, Diabetes and Metabolism (M.R., A.A.R.), University of South Carolina School of Medicine, Columbia, South Carolina 29203; Division of Endocrinology (N.A., M.C.), The University of Texas Medical Branch, Galveston, Texas 77555; Department of Experimental Biomedicine and Clinical Neurosciences (A.M.G.), University of Palermo, Palermo 90127, Italy; Department of Drug Sciences (I.B.), University of Catania, Catania 90125, Italy; Laboratory for Molecular Genetics and Radiobiology (E.R.I.), Vinca Institute, University of Belgrade, Belgrade 11000, Serbia; Department of Hypertension (M.B.), Medical University of Lodz, Lodz 90-549, Poland; and Department of Biomedical and Biotechnological Sciences (G.L.V.), University of Catania, Catania 90125, Italy.
Abstract
CONTEXT: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. OBJECTIVE: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). DESIGN AND SETTING: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. MAIN OUTCOME MEASURE(S): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. RESULTS: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. CONCLUSIONS: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.
CONTEXT: Liraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated. OBJECTIVE: We evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). DESIGN AND SETTING: A prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. MAIN OUTCOME MEASURE(S): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed. RESULTS: The addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c. CONCLUSIONS: In a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.
Authors: Manfredi Rizzo; Alberto J L Macario; Everly Conway de Macario; Ioanna Gouni-Berthold; Heiner K Berthold; Giovam Battista Rini; Giovanni Zummo; Francesco Cappello Journal: Curr Pharm Des Date: 2011-11 Impact factor: 3.116
Authors: Giuseppina Novo; Francesco Cappello; Manfredi Rizzo; Giovanni Fazio; Sabrina Zambuto; Enza Tortorici; Antonella Marino Gammazza; Antonella M Gammazza; Simona Corrao; Giovanni Zummo; Everly C De Macario; Alberto J L Macario; Pasquale Assennato; Salvatore Novo; Giovanni Li Volti; Giovanni L Volti Journal: Transl Res Date: 2011-02-05 Impact factor: 7.012
Authors: Hisko Oeseburg; Rudolf A de Boer; Hendrik Buikema; Pim van der Harst; Wiek H van Gilst; Herman H W Silljé Journal: Arterioscler Thromb Vasc Biol Date: 2010-05-06 Impact factor: 8.311
Authors: Manfredi Rizzo; Manisha Chandalia; Angelo Maria Patti; Vittoria Di Bartolo; Ali A Rizvi; Giuseppe Montalto; Nicola Abate Journal: Cardiovasc Diabetol Date: 2014-02-22 Impact factor: 9.951
Authors: Ninon Taylor; Iris Kremser; Simon Auer; Gregor Hoermann; Richard Greil; Elisabeth Haschke-Becher; Harald Esterbauer; Lukas Kenner; Hannes Oberkofler Journal: J Acquir Immune Defic Syndr Date: 2017-05-01 Impact factor: 3.731
Authors: Nienke M A Idzerda; Lindsay E Clegg; Adrian F Hernandez; George Bakris; Robert C Penland; David W Boulton; M Angelyn Bethel; Rury R Holman; Hiddo J L Heerspink Journal: Diabetes Obes Metab Date: 2020-02-03 Impact factor: 6.577
Authors: Zhong-Cheng Luo; Jean-François Bilodeau; Anne Monique Nuyt; William D Fraser; Pierre Julien; Francois Audibert; Lin Xiao; Carole Garofalo; Emile Levy Journal: Sci Rep Date: 2015-12-08 Impact factor: 4.379
Authors: Lee Kyung Kim; Eun Roh; Min Joo Kim; Min Kyeong Kim; Kyeong Seon Park; Soo Heon Kwak; Young Min Cho; Kyong Soo Park; Hak Chul Jang; Hye Seung Jung Journal: J Diabetes Investig Date: 2016-06-04 Impact factor: 4.232